Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Merck & Co., Inc. -2.07%

Merck & Co., Inc.

MRK

115.46

-2.07%

Feb 23 (Reuters) - Drugmaker Merck MRK.N is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.

One division will house its cancer drugs, including Keytruda, while the other will sell its non-cancer products.

Merck did not respond to a Reuters request for comment immediately.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.